Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ChromaDex Corporation

< Previous 1 2 3 Next >
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Participate in the LD Micro Invitational XIII
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports First Quarter 2023 Financial Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
A Letter from the ChromaDex Chief Executive Officer
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.